StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)

Close on Nov 16, 2026Market cap $1.52BP/E –Yield –

GeneDx ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

GeneDx's ebitda for the twelve months ending Jun 30, 2026 was -$81.47M, down 666.5% year over year. For fiscal 2025 it was -$3.48M. The highest annual figure on record is -$3.48M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.48M–
FY2024Dec 31, 2024-$15.31M–
FY2023Dec 31, 2023-$160.90M–
FY2022Dec 31, 2022-$617.65M–
FY2021Dec 31, 2021-$424.34M–
FY2020Dec 31, 2020-$230.26M–
FY2019Dec 31, 2019-$24.01M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.36M-227.5%
Q1 FY2026Mar 31, 2026-$54.77M–
Q4 FY2025Dec 31, 2025-$11.46M-205.8%
Q3 FY2025Sep 30, 2025-$881.00K–
Q2 FY2025Jun 30, 2025$11.26M–
Q1 FY2025Mar 31, 2025-$2.35M–
Q4 FY2024Dec 31, 2024$10.83M–
Q3 FY2024Sep 30, 2024-$5.36M–
Q2 FY2024Jun 30, 2024-$8.87M–
Q1 FY2024Mar 31, 2024-$11.92M–
Q4 FY2023Dec 31, 2023-$23.07M–
Q3 FY2023Sep 30, 2023-$37.80M–
Q2 FY2023Jun 30, 2023-$44.80M–
Q1 FY2023Mar 31, 2023-$55.23M–
Q4 FY2022Dec 31, 2022-$294.31M–
Q3 FY2022Sep 30, 2022-$83.82M–
Q2 FY2022Jun 30, 2022-$156.02M–
Q1 FY2022Mar 31, 2022-$83.50M–
Q4 FY2021Dec 31, 2021-$109.99M–
Q3 FY2021Sep 30, 2021-$82.77M–
Q2 FY2021Jun 30, 2021-$39.83M–
Q1 FY2021Mar 31, 2021-$191.76M–
Q4 FY2020Dec 31, 2020-$121.46M–
Q3 FY2020Sep 30, 2020-$52.95M–

More GeneDx figures

See a number that looks wrong?